E. Fitzpatrick

发表

Interference-Free HER2 ECD as a Serum Biomarker in Breast Cancer

B. Czerniecki, Hongtao Zhang, Xiaowei Xu, 2013, Journal of molecular biomarkers & diagnosis.

Inhibition of CD4+CD25+ Regulatory T Cell Function and Conversion into Th1-Like Effectors by a Toll-Like Receptor-Activated Dendritic Cell Vaccine

B. Czerniecki, Shuwen Xu, M. K. Lee, 2013, PloS one.

Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial

S. Weinstein, B. Czerniecki, A. DeMichele, 2016, Clinical Cancer Research.

High-avidity antitumor T-cell generation by toll receptor 8-primed, myeloid- derived dendritic cells is mediated by IL-12 production.

B. Czerniecki, Shuwen Xu, G. Koski, 2006, Surgery.

Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2

P. Ross-Macdonald, K. McIntyre, G. Trainor, 2012, Leukemia.

HER‐2 pulsed dendritic cell vaccine can eliminate HER‐2 expression and impact ductal carcinoma in situ

H. Nisenbaum, S. Weinstein, B. Czerniecki, 2012, Cancer.

Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER 2 pos Ductal Carcinoma In Situ Independent of Route : Results of Randomized Selection Design Trial

S. Weinstein, B. Czerniecki, A. DeMichele, 2016 .

Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer

Noah D. Goodman, B. Czerniecki, A. DeMichele, 2015, Breast Cancer Research.

Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer

B. Czerniecki, A. DeMichele, Shuwen Xu, 2015, Breast Cancer Research.

Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ERpos/HER2pos early breast cancer

B. Czerniecki, A. DeMichele, R. Mick, 2017, Oncoimmunology.

A Novel Dendritic Cell-based Immunization Approach for the Induction of Durable Th1-polarized Anti-HER-2/neu Responses in Women With Early Breast Cancer

H. Nisenbaum, S. Weinstein, B. Czerniecki, 2012, Journal of immunotherapy.

Progressive loss of anti-HER2 CD4+ T-helper type 1 response in breast tumorigenesis and the potential for immune restoration

B. Czerniecki, M. Feldman, R. Mick, 2015, Oncoimmunology.

A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor

Martin C. Wright, A. Yamniuk, M. Doyle, 2011, mAbs.

Response to HER-2 Pulsed DC1 Vaccines is Predicted by Both HER-2 and Estrogen Receptor Expression in DCIS

H. Nisenbaum, B. Czerniecki, K. Fox, 2013, Annals of Surgical Oncology.

An ACE2-IgG4 Fc Fusion Protein Demonstrates Strong Binding to All Tested SARS-CoV-2 Variants and Reduced Lung Inflammation in Animal Models of SARS-CoV-2 and Influenza

Dong Yang, R. Schinazi, L. Bassit, 2022, Pathogens & immunity.

Cryopreservation of activated DC1 makes large scale dendritic cell vaccines feasible in cancer therapy

B. Czerniecki, Shuwen Xu, J. Datta, 2015 .